Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.

Misdirected catalytic activity of histone methyltransferase Dot1L is believed to be causative for a subset of highly aggressive acute leukemias. Targeting the catalytic domain of Dot1L represents a potential therapeutic approach for these leukemias. In the context of a comprehensive Dot1L hit finding strategy, a knowledge-based virtual screen of the Dot1L SAM binding pocket led to the discovery of , a non-nucleoside fragment mimicking key interactions of SAM bound to Dot1L. Fragment linking of and , an induced back pocket binder identified in earlier studies, followed by careful ligand optimization led to the identification of , a highly potent, selective and structurally novel Dot1L inhibitor.